scholarly article | Q13442814 |
review article | Q7318358 |
P356 | DOI | 10.1016/S0006-3223(02)01741-9 |
P8608 | Fatcat ID | release_kxqmes4q6jfv3gsnb2kf54jcui |
P698 | PubMed publication ID | 12706953 |
P50 | author | Susan L McElroy | Q56816544 |
Paul E. Keck | Q111738411 | ||
P2093 | author name string | Erik B Nelson | |
P2860 | cites work | Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial | Q28208895 |
A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder | Q29394100 | ||
Effectiveness and safety of long-term antidepressant treatment in bipolar disorder | Q30999313 | ||
A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. | Q33844681 | ||
Historical perspectives and natural history of bipolar disorder | Q33920209 | ||
A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders | Q33927263 | ||
Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? | Q33942947 | ||
Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression | Q33949128 | ||
Bipolar depression: pharmacotherapy and related therapeutic strategies | Q34052825 | ||
Unitary or binary nature of classification of depressive illness and its implications for the scope of manic depressive disorder | Q34211850 | ||
New perspectives in the acute treatment of bipolar depression. | Q35073842 | ||
Indicators of suicide over 10 years in a specialist mood disorders unit sample. | Q40667500 | ||
A novel augmentation strategy for treating resistant major depression | Q43514882 | ||
Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients | Q43540822 | ||
Antidepressant-induced mania in bipolar patients: identification of risk factors. | Q43622365 | ||
Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression | Q43761132 | ||
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy | Q43846648 | ||
Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers | Q43931805 | ||
Olanzapine versus divalproex in the treatment of acute mania | Q44013092 | ||
Bipolar depression and antidepressant-induced mania: a naturalistic study. | Q44136511 | ||
A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder | Q44403599 | ||
Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study. | Q51960801 | ||
Antidepressant-Associated Mania and Psychosis Resulting in Psychiatric Admissions | Q56209637 | ||
The nature of bipolar depression: implications for the definition of melancholia | Q57244721 | ||
Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination | Q70504944 | ||
Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression | Q73317622 | ||
The treatment of bipolar depression | Q73617031 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | bipolar depression | Q56014658 |
P304 | page(s) | 671-679 | |
P577 | publication date | 2003-04-01 | |
P1433 | published in | Biological Psychiatry | Q4914961 |
P1476 | title | Advances in the pharmacologic treatment of bipolar depression | |
P478 | volume | 53 |
Q36424640 | A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression |
Q35111584 | Acceleration and augmentation strategies for treating bipolar depression |
Q46055786 | Adjunctive aripiprazole in bipolar I depression |
Q36624146 | Antidepressants and suicidal behavior in bipolar disorder |
Q44727578 | Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine |
Q45272320 | Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder |
Q42257957 | Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test |
Q83200405 | Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers |
Q46200033 | Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression |
Q64126908 | Pramipexole: augmentation in the treatment of depressive symptoms |
Q24643545 | Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder |
Q35164720 | The combination of olanzapine and fluoxetine in mood disorders |
Q35936247 | Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence |
Q82351280 | Treatment-resistant bipolar disorder |
Q79351262 | [Monitoring mood regulating drugs in bipolar disorder] |